Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Maxalt 10mg Plus Caffeine 75mg in the Acute Treatment of Migraine Headache

This study has been completed.
Sponsor:
Collaborator:
Merck Sharp & Dohme Corp.
Information provided by (Responsible Party):
Diamond Headache Clinic
ClinicalTrials.gov Identifier:
NCT00471952
First received: May 8, 2007
Last updated: April 24, 2012
Last verified: April 2012
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been completed.
  Study Completion Date: April 2008
  Primary Completion Date: February 2008 (Final data collection date for primary outcome measure)